PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology

Abstract

Steatotic liver disease (SLD), particularly metabolic dysfunction-associated SLD, represents a significant public health concern worldwide. Among the various factors implicated in the development and progression of this condition, the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene has emerged as a critical player. Variants of PNPLA3 are associated with altered lipid metabolism, leading to increased hepatic fat accumulation and subsequent inflammation and fibrosis. Understanding the role of PNPLA3 not only enhances our comprehension of the pathomechanisms driving SLD but also informs potential therapeutic strategies. The molecular mechanisms through which PNPLA3 variants contribute to lipid dysregulation and hepatocyte injury in SLD are critically discussed in the present review article. We extensively analyze clinical cohorts and population-based studies underpinning the association between PNPLA3 polymorphisms and the risk of developing SLD, and its liver-related and protean extrahepatic outcomes, in concert with other risk modifiers, notably including age, sex, and ethnicity in adults and children. We also discuss the increasingly recognized role played by the PNPLA3 gene in liver transplantation, autoimmune hepatitis, and acquired immunodeficiency syndrome. Finally, we examine the clinical implications of PNPLA3 diagnostics regarding risk stratification and targeted therapies for patients affected by SLD in the context of precision medicine approaches.

Keywords

Cirrhosis / extrahepatic outcomes / ethnicity / hepatocellular carcinoma / insulin resistance / liver transplantation / MASLD / PNPLA3 gene / cardio-nephro-metabolic syndrome / precision medicine / sex differences / steatotic liver disease

References

[1] MiaoL,ByrneCD,ZhengMH.Current status and future trends of the global burden of MASLD.Trends Endocrinol Metab2024;35:697-707

[2] Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).J Hepatol2024;81:492-542

[3] CooremanMP,FrancqueSM.MASLD/MASH and type 2 diabetes: two sides of the same coin? From single PPAR to pan-PPAR agonists.Diabetes Res Clin Pract2024;212:111688

[4] LavradoNC,CardosoCRL.Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.Liver Int2024;44:1042-50

[5] IsraelsenM,TsochatzisEA.Steatotic liver disease.Lancet2024;404:1761-78

[6] KozlitinaJ.Global epidemiological impact of PNPLA3 I148M on liver disease. Liver Int 2024.

[7] XiaM,Pla-PalacínI.Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy.Front Cell Dev Biol2024;12:1423936 PMCID:PMC11422722

[8] BaulandeS,LucasM.Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage.J Biol Chem2001;276:33336-44

[9] MongaSPS.Chapter 20 - Molecular basis of liver disease. In: Essential concepts in molecular pathology. 2020; pp. 345-65.

[10] ShermanDJ,MamroshJL.The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.Proc Natl Acad Sci USA2024;121:e2318619121 PMCID:PMC11067037

[11] LulićAM.The PNPLA family of enzymes: characterisation and biological role.Arh Hig Rada Toksikol2023;74:75-89 PMCID:PMC10291501

[12] GouY,ZhaoJ.PNPLA3-I148M variant promotes the progression of liver fibrosis by inducing mitochondrial dysfunction.Int J Mol Sci2023;24:9681 PMCID:PMC10253263

[13] CaonE,HodgettsH.Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.J Hepatol2024;80:941-56

[14] KabbaniM,SteenselsS.Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice.Cell Rep2022;40:111321 PMCID:PMC11587767

[15] LiY,KurilshikovA.Genome-wide studies reveal genetic risk factors for hepatic fat content.Genom Proteom Bioinf2024;22:qzae031

[16] LiaoS,LiuZ.Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.J Clin Lab Anal2022;36:e24626 PMCID:PMC9459258

[17] LeeY,ChoeEK.Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population.Sci Rep2024;14:9753 PMCID:PMC11056367

[18] CherubiniA,JamialahmadiO.Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.Nat Med2023;29:2643-55

[19] HeS,LiJZ.A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.J Biol Chem2010;285:6706-15 PMCID:PMC2825465

[20] JohnsonSM,McMahonCE.PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein.Nat Commun2024;15:4847 PMCID:PMC11156938

[21] AgliaruloI.Golgi apparatus regulates plasma membrane composition and function.Cells2022;11:368 PMCID:PMC8834378

[22] WitzelHR,HartmannN.PNPLA3(I148M) inhibits lipolysis by perilipin-5-dependent competition with ATGL.Cells2022;12:73 PMCID:PMC9818421

[23] LeeSO,KangJH.The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells.Mol Cancer Res2014;12:527-38 PMCID:PMC4407472

[24] LuukkonenPK,AhlholmN.The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans.Cell Metab2023;35:1887-96.e5

[25] BruschiFV,TardelliM.The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells.Hepatology2017;65:1875-90

[26] PingitoreP,MottaBM.PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis.Hum Mol Genet2016;25:5212-22 PMCID:PMC5886043

[27] HemmannS,RoderfeldM.Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies.J Hepatol2007;46:955-75

[28] ThieleND,SteinsD.TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice.Sci Rep2017;7:714 PMCID:PMC5428806

[29] RadyB,DharD.PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells.PLoS One2021;16:e0260721 PMCID:PMC8654208

[30] KovarovaM,KönigsrainerA.The genetic variant I148M in PNPLA3 is associated with increased hepatic retinyl-palmitate storage in humans.J Clin Endocrinol Metab2015;100:E1568-74

[31] ChenG.The link between hepatic vitamin a metabolism and nonalcoholic fatty liver disease.Curr Drug Targets2015;16:1281-92

[32] ChenG,WeiskirchenR.Vitamin A: too good to be bad?.Front Pharmacol2023;14:1186336 PMCID:PMC10239981

[33] PirazziC,MottaBM.PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells.Hum Mol Genet2014;23:4077-85 PMCID:PMC4082369

[34] MondulA,MerloA.PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity.J Nutr2015;145:1687-91 PMCID:PMC4516767

[35] BonaciniM,KariS,KohlaM.Racial differences in prevalence and severity of non-alcoholic fatty liver disease.World J Hepatol2021;13:763-73 PMCID:PMC8326166

[36] CaldwellSH,PatrieJT.Is NASH underdiagnosed among African Americans?.Am J Gastroenterol2002;97:1496-500

[37] LazoM,AlvarezCS.Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population.Liver Int2022;42:1470-4 PMCID:PMC9241623

[38] ZhangH,ShapiroMD.Global burden of metabolic diseases, 1990-2021.Metabolism2024;160:155999

[39] KallwitzER,KuniholmMH.American ancestry is a risk factor for suspected nonalcoholic fatty liver disease in Hispanic/Latino adults.Clin Gastroenterol Hepatol2019;17:2301-9

[40] ShenJH,LiD,JingL.The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis.J Lipid Res2015;56:167-75 PMCID:PMC4274064

[41] GrimaudoS,PennisiG.Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2020;18:935-44.e3

[42] HuangZ,ZhangG,NongB.Correlation between PNPLA3 rs738409 polymorphism and hepatocellular carcinoma: a meta-analysis of 10,330 subjects.Int J Biol Markers2019;34:117-22

[43] GusdonAM,ChenJ,QuS.Mitochondrial haplogroup G is associated with nonalcoholic fatty liver disease, while haplogroup A mitigates the effects of PNPLA3.Endocrinol Diabetes Metab2021;4:e00187 PMCID:PMC7831202

[44] LangS,ZhangX.Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease.Liver Int2021;41:1576-91 PMCID:PMC8947846

[45] KrawczykM,ZimmerV.Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease.J Hepatol2011;55:299-306

[46] WangP,LiY,ShenN.PNPLA3 rs738409 is not associated with the risk of hepatocellular carcinoma and persistent infection of hepatitis B virus (HBV) in HBV-related subjects: a case-control study and meta-analysis on Asians.Gene2020;742:144585

[47] YiS,ZhuY.Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study.Virol J2024;21:22 PMCID:PMC10799397

[48] LisboaQC,PereiraPA.PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease.World J Hepatol2020;12:792-806 PMCID:PMC7643213

[49] IdilmanR,KabacamG,ElhanAH.The role of PNPLA3 (rs738409) c>g variant on histological progression of non-alcoholic fatty liver disease.Hepatol Forum2020;1:82-7 PMCID:PMC9349489

[50] PennisiG,CammàC.PNPLA3 rs738409 C>G variant predicts fibrosis progression by noninvasive tools in nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2021;19:1979-81

[51] SalariN,MansouriK.Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis.BMC Endocr Disord2021;21:125 PMCID:PMC8214766

[52] LiG,ZhuPW.PNPLA3 rs738409 C>G variant influences the association between visceral fat and significant fibrosis in biopsy-proven nonalcoholic fatty liver disease.J Clin Transl Hepatol2022;10:439-48 PMCID:PMC9240254

[53] KimHS,ByunJ.Synergistic associations of PNPLA3 I148M Variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality.JAMA Netw Open2022;5:e2234221 PMCID:PMC9530967

[54] ChenVL,MillerMJ.PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis.Gastroenterology2023;164:966-77.e17 PMCID:PMC10550206

[55] KooBK,KwakSH,ParkJH.Innovative Target Exploration of NAFLD (ITEN) consortiumLong-term effect of PNPLA3 on the aggravation of nonalcoholic fatty liver disease in a biopsy-proven cohort.Clin Gastroenterol Hepatol2023;21:1105-7.e3

[56] ZhaoY,MaJ,ZhaoY.Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: a meta-analysis of twenty studies.Medicine2023;102:e33110 PMCID:PMC9997767

[57] RossoC,BiroloG.Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2023;21:3314-21.e3

[58] SekoY,ShimaT.The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: a multicentre cohort study.Liver Int2023;43:2210-9

[59] ChalasaniN,LoombaR.PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.Hepatology2024;80:1212-26

[60] BrilF,LomonacoR,GodinezLeiva E.Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants.JHEP Rep2024;6:101092 PMCID:PMC11252529

[61] ElmansouryN,KamalA.Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR variants to MASLD severity in an Egyptian population.Genes2024;15:455 PMCID:PMC11049340

[62] Kocas-KilicarslanZN,FaccioliLAP.Polymorphisms associated with metabolic dysfunction-associated steatotic liver disease influence the progression of end-stage liver disease.Gastro Hep Adv2024;3:67-77 PMCID:PMC10827334

[63] SekoY,ShimaT.Differential effects of genetic polymorphism on comorbid disease in metabolic dysfunction-associated steatotic liver disease.Clin Gastroenterol Hepatol2024;22:1436-43.e4

[64] PelusiS,RondenaJ.Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD.Clin Gastroenterol Hepatol2024;22:2231-9.e4

[65] SureshD,MillerMJ,ChenVL.Associations between metabolic hyperferritinaemia, fibrosis-promoting alleles and clinical outcomes in steatotic liver disease.Liver Int2024;44:389-98 PMCID:PMC10872664

[66] LonardoA,ScaglioniF.Hepatic steatosis and insulin resistance: does etiology make a difference?.J Hepatol2006;44:190-6

[67] VeskovićM,HrnčićD,MacutD.The interconnection between hepatic insulin resistance and metabolic dysfunction-associated steatotic liver disease-the transition from an adipocentric to liver-centric approach.Curr Issues Mol Biol2023;45:9084-102 PMCID:PMC10670061

[68] SemmlerG,OberkoflerH.PNPLA3 and SERPINA1 variants are associated with severity of fatty liver disease at first referral to a tertiary center.J Pers Med2021;11:165 PMCID:PMC7999282

[69] Jansson-KnodellCL,McIntyreAD,HegeleRA.Apolipoprotein B and PNPLA3 double heterozygosity in a father-son pair with advanced nonalcoholic fatty liver disease.Hepatology2020;71:383-5

[70] ChouikY,RadenneS,MoulinP.Combination of heterozygous APOB gene mutation with PNPLA3 and TM6SF2 variants promotes steatotic liver disease, cirrhosis and HCC development.Liver Int2024;44:1474-7

[71] VolkertI,SchneiderC.Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.Hepatology2024;79:898-911

[72] BellanM,BarbagliaMN.Severity of nonalcoholic fatty liver disease in type 2 diabetes mellitus: relationship between nongenetic factors and PNPLA3/HSD17B13 polymorphisms.Diabetes Metab J2019;43:700-10 PMCID:PMC6834828

[73] SekoY,TochikiN.Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.Liver Int2020;40:1686-92

[74] MantovaniA,LonardoA.Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis?.Int J Mol Sci2016;17:217 PMCID:PMC4783949

[75] KaramfilovaV,AssyovY.PNPLA3 I148M polymorphism in patients with nonalcoholic fatty liver disease, obesity and prediabetes.J Gastrointestin Liver Dis2019;28:433-8

[76] WuJT,XieXJ,XinYN.Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.Lipids Health Dis2020;19:29 PMCID:PMC7041191

[77] AjmeraV,BettencourtR,RichardsL.The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography.Aliment Pharmacol Ther2021;54:68-77 PMCID:PMC8985656

[78] MoonS,JooSK.A PNPLA3 polymorphism confers lower susceptibility to incident diabetes mellitus in subjects with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2022;20:682-91.e8

[79] MantovaniA,MargaritaS.Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction.Aliment Pharmacol Ther2023;57:1093-102

[80] MantovaniA,CsermelyA.Association between PNPLA3 rs738409 variant and 5-year estimated glomerular filtration rate decline in post-menopausal women with type 2 diabetes: a panel-data analysis.Nutr Metab Cardiovasc Dis2023;33:1093-7

[81] TaiJ,ChenWT.Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype.Cancer Sci2024;115:564-74 PMCID:PMC10859614

[82] AgogliaL,BarbosaL.Psoriasis and steatotic liver disease: are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?.Ann Hepatol2024;29:101477

[83] MantovaniA.PNPLA3 rs738409 polymorphism and kidney dysfunction: an association beyond nonalcoholic fatty liver disease?.Metab Target Organ Damage2023;3:18

[84] DemirtasCO.Decoding 17-beta-hydroxysteroid dehydrogenase 13: a multifaceted perspective on its role in hepatic steatosis and associated disorders.J Clin Transl Hepatol2024;12:857-64 PMCID:PMC11491501

[85] HuangHYR,ZhangD.Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach.JHEP Rep2025;7:101243

[86] MahdessianH,PopovS.TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.Proc Natl Acad Sci USA2014;111:8913-8 PMCID:PMC4066487

[87] SmagrisE,BasuRayS,HobbsHH.Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins.J Biol Chem2016;291:10659-76 PMCID:PMC4865914

[88] SlizE,WürtzP.NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.Hum Mol Genet2018;27:2214-23 PMCID:PMC5985737

[89] ChandrasekaranP.The pivotal role of the membrane-bound O-acyltransferase domain containing 7 in non-alcoholic fatty liver disease.Livers2024;4:1-14

[90] LiYM,WangJ.Genetic variations and nonalcoholic fatty liver disease: field synopsis, systematic meta-analysis, and epidemiological evidence.Biomed Environ Sci2024;37:762-73

[91] AjmeraV.Advances in the genetics of nonalcoholic fatty liver disease.Curr Opin Gastroenterol2023;39:150-5 PMCID:PMC10167543

[92] BridiL,TesfaiK.The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.Aliment Pharmacol Ther2024;60:369-77 PMCID:PMC11236495

[93] YuanC,AnB.Association between LYPLAL1 rs12137855 polymorphism with ultrasound-defined non-alcoholic fatty liver disease in a Chinese Han population.Hepat Mon2015;15:e33155 PMCID:PMC4772303

[94] DanpanichkulP,PrasitsumritV,WijarnpreechaK.Long-term outcomes and risk modifiers of MASLD between lean and non-lean populations. Clin Mol Hepatol 2024.

[95] SatoS,SasadaT.Epidemiological study on the interaction between the PNPLA3 (rs738409) and gut microbiota in metabolic dysfunction-associated steatotic liver disease.Genes2024;15:1172 PMCID:PMC11430940

[96] NavarroJ.HIV and liver disease.AIDS Rev2022;25:87-96

[97] ChoochuayK,PuangpetchA.Associations of PNPLA3 and LEP genetic polymorphisms with metabolic-associated fatty liver disease in Thai people living with human immunodeficiency virus.World J Hepatol2024;16:366-78 PMCID:PMC10989307

[98] vanEekeren LE,VosWAJW.Liver steatosis is prevalent in lean people with HIV and associated with exposure to antiretroviral treatment-a cross-sectional study.Open Forum Infect Dis2024;11:ofae266 PMCID:PMC11167668

[99] GuaraldiG,BallestriS.Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease.Arch Med Res2011;42:690-7

[100] HanWM,ChuaypenN,AvihingsanonA.HIV-NAT 006 teamAssociation of PNPLA3 risk variant with steatotic liver disease among lean people with HIV mono-infection.J Hepatol2024;S0168-8278(24)02495-4

[101] ShermanKE,MeedsH.PNPLA3 single nucleotide polymorphism prevalence and association with liver disease in a diverse cohort of persons living with HIV.Biology2021;10:242 PMCID:PMC8004031

[102] PaklarN,Filipec-KanizajT.The outcomes of liver transplantation in severe metabolic dysfunction-associated steatotic liver disease patients.Biomedicines2023;11:3096 PMCID:PMC10669065

[103] LonardoA,PettaS,ByrneCD.Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.Nat Rev Endocrinol2022;18:638-50

[104] MakinoK,OgisoS.Combination of risk alleles of PNPLA3, TM6SF2, and HSD17B13 of donors can predict recurrence of steatotic liver disease after liver transplantation.Hepatol Res2024;54:1148-57

[105] YooT,YiNJ.Impact of PNPLA3 (rs738409-G) polymorphism on post-transplant outcomes after liver transplantation for alcohol-related liver disease.Clin Transplant2020;34:e14011

[106] TangS,MeiTT.Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis.BMC Med Genet2020;21:163 PMCID:PMC7433068

[107] LiJ,JiC.Effect of the patatin-like phospholipase domain containing 3 gene (PNPLA3) I148M polymorphism on the risk and severity of nonalcoholic fatty liver disease and metabolic syndromes: a meta-analysis of paediatric and adolescent individuals.Pediatr Obes2020;15:e12615

[108] MansoorS,DiGuglielmo M.The PNPLA3 rs738409 variant but not MBOAT7 rs641738 is a risk factor for nonalcoholic fatty liver disease in obese U.S. children of hispanic ethnicity.Pediatr Gastroenterol Hepatol Nutr2021;24:455-69 PMCID:PMC8443857

[109] SchenkerRB,SchmidtKA,KohliR.Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity.Liver Int2024;44:1768-74 PMCID:PMC11251846

[110] LeeKJ,KimNY.Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.Pediatr Obes2022;17:e12852

[111] MarzuilloP,GuarinoS.Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity.Pediatr Obes2019;14:e12539

[112] HuangJF.Editorial: PNPLA3 genotype and liver diseases-more than non-alcoholic fatty liver disease.Aliment Pharmacol Ther2020;52:390-1

[113] AzariadisK,LyberopoulouA.PNPLA3 I148 M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality.J Transl Autoimmun2024;9:100243 PMCID:PMC11225017

[114] MederackeYS.Editorial: PNPLA3 genotype and liver diseases-more than non-alcoholic fatty liver disease. Authors’ reply.Aliment Pharmacol Ther2020;52:391-2

[115] ChenVL.Integrating PNPLA3 into clinical risk prediction. Liver Int 2024.

[116] SalamehH,ErwinA.PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease.Am J Gastroenterol2015;110:846-56

[117] RinellaME,RatziuV.A multisociety Delphi consensus statement on new fatty liver disease nomenclature.Hepatology2023;78:1966-86

[118] LiuWY,PanXY.Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.J Gastroenterol Hepatol2020;35:1057-64

[119] RashuEB,HetlandLE.Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.Clin Res Hepatol Gastroenterol2024;48:102389

[120] CherubiniA,DellaTorre S.Sex-specific effects of PNPLA3 I148M. Liver Int 2024.

[121] OlloquequiJ,Díaz-PeñaR.Pharmacogenetic variation and its clinical relevance in a Latin American rural population.Int J Mol Sci2022;23:11758 PMCID:PMC9570141

[122] YuanL.PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver.Hepatobiliary Surg Nutr2020;9:353-6 PMCID:PMC7262620

[123] DongXC.PNPLA3-A potential therapeutic target for personalized treatment of chronic liver disease.Front Med2019;6:304 PMCID:PMC6927947

[124] MutoN,KudoM.A pilot study assessing the possible combined effect of physical activity and PNPLA3 rs738409 polymorphism on the risk for non-alcoholic fatty liver disease in the Japanese elderly general population.Diabetes Metab Syndr Obes2020;13:333-41 PMCID:PMC7024805

[125] PaoliniE,MeroniM.The I148M PNPLA3 variant mitigates niacin beneficial effects: how the genetic screening in non-alcoholic fatty liver disease patients gains value.Front Nutr2023;10:1101341 PMCID:PMC10018489

[126] MurrayJK,LiuL.Identification and optimization of a minor allele-specific siRNA to prevent PNPLA3 I148M-driven nonalcoholic fatty liver disease.Nucleic Acid Ther2021;31:324-40

[127] ZhangG,HeF.LDL-C and TC mediate the risk of PNPLA3 inhibition in cardiovascular diseases.J Clin Endocrinol Metab2024;dgae264

[128] WangY,HudsonH.PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis.J Hepatol2024;S0168-8278(24)02707